Holen Sie sich die Stockscreener-App
5.085
0.59%
-0.035
Xeris Biopharma Holdings Inc Aktie (XERS) Neueste Nachrichten
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Xeris Biopharma Holdings Inc. Stock Analysis and ForecastSuperior returns - Autocar Professional
What analysts say about Xeris Biopharma Holdings Inc. stockAccelerated capital growth - jammulinksnews.com
Is Xeris Biopharma Holdings Inc. a good long term investmentFree Technical Analysis Support - jammulinksnews.com
How Xeris Biopharma Holdings Inc. stock performs during market volatilitySmall Risk Large Return Trades - Newser
Xponance Inc. Invests $57,000 in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
What drives Xeris Biopharma Holdings Inc. stock priceBreakout stock performance - Autocar Professional
how xeris biopharma holdings inc. stock performs during market volatilityMarket Timing Advice - Newser
why xeris biopharma holdings inc. stock attracts strong analyst attentionMassive Upside Selection - Newser
Brown Advisory Inc. Has $630,000 Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Why Xeris Biopharma Holdings Inc. stock attracts strong analyst attentionProfessional Stock Screener - Newser
What makes Xeris Biopharma Holdings Inc. stock price move sharplyBreakout Momentum Stocks - Newser
A Piece Of The Puzzle Missing From Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) 25% Share Price Climb - simplywall.st
Xeris Biopharma's 7% Spike: Unraveling the Mysterious Move - AInvest
Wealth Enhancement Advisory Services LLC Has $172,000 Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma's 10% Spike: A Technical and Market Flow Deep Dive - AInvest
Xeris Biopharma (NASDAQ:XERS) versus Mangoceuticals (NASDAQ:MGRX) Head to Head Review - Defense World
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Rhumbline Advisers Increases Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Wealth Enhancement Advisory Services LLC Raises Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma: Great Numbers, Great Technologies, And Suitable For Long-Term Investing - Seeking Alpha
Xeris Biopharma (NASDAQ:XERS) Stock Price Up 8.4% Following Insider Buying Activity - Defense World
Pallas Capital Advisors LLC Acquires New Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Squarepoint Ops LLC Has $138,000 Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Two Sigma Advisers LP Makes New Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Leerink Partnrs Estimates Xeris Biopharma FY2025 Earnings - Defense World
Leerink Partnrs Forecasts Lower Earnings for Xeris Biopharma - Defense World
Xeris Biopharma (NASDAQ:XERS) Stock Price Down 5.5%Should You Sell? - MarketBeat
Leerink Partners raises Xeris Pharmaceuticals stock price target By Investing.com - Investing.com UK
Transcript : Xeris Biopharma Holdings, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 01 - MarketScreener
Xeris at Jefferies Conference: Strategic Growth and Future Prospects By Investing.com - Investing.com Canada
xeris biopharma holds annual meeting, elects directors By Investing.com - Investing.com South Africa
xeris biopharma holds annual meeting, elects directors - Investing.com
Xeris Pharmaceuticals Holds 2025 Annual Stockholders Meeting - TipRanks
Xeris Biopharma touts ambitious growth plan, promising hypothyroidism drug - Crain's Chicago Business
Xeris Biopharma projects $1 billion Recorlev revenue by 2035 - Investing.com South Africa
Xeris Biopharma Holdings, Inc. Rings the Closing Bell - Nasdaq
Transcript : Xeris Biopharma Holdings, Inc.Analyst/Investor Day - marketscreener.com
Xeris Biopharma Holdings, Inc. Reaffirms Revenue Guidance for the Year 2025 - marketscreener.com
Xeris Biopharma Holdings Shares Fall; 2025 Revenue Guidance Reaffirmed, Long-Term Outlook Set - marketscreener.com
4.79%
0.24%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):